Teva Files Paragraph IV ANDA For Avapro

Law360, New York (July 20, 2004, 12:00 AM EDT) -- Israeli drug maker Teva Pharmaceuticals has filed an application to make a generic version of Sanofi-Synthelabo’s hypertension drug Avapro.

Teva filed an Abbreviated New Drug Application (ANDA) with a Paragraph IV certification with the U.S. Food and Drug Administration for the marketing in the U.S.of a generic version of the drug Sanofi-Synthelabo said.

The filing does not challenge Sanofi-Synthelabo’s basic product patent that expires in 2011, but alleges only that the Teva formulation does not infringe the pharmaceutical formulation patent expiring in 2015, Sanofi-Synthelabo said....
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.